Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2022-09-08 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-09-08 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a collaboration between Tetra Bio-Pharma Inc. and Cellvera to develop a potential oral combination treatment for COVID-19 patients. It describes the drug candidates, their mechanisms, and the partnership's goals. There is no indication of financial results, regulatory filings, management changes, or shareholder voting results. The content is promotional and informative about a new drug development partnership, typical of a Capital/Financing Update or a general corporate announcement. However, since it focuses on a development collaboration and drug pipeline update without explicit fundraising or capital structure changes, it aligns best with a Capital/Financing Update (CAP) as it relates to company development activities and potential future financing implications. The document is not a report, transcript, or regulatory filing, and it is longer than 5,000 characters, so it is not a mere announcement of a report publication. Therefore, the most appropriate classification is CAP with high confidence.
2022-09-06 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a FORM 51-102F3 Material Change Report filed by Tetra Bio-Pharma Inc. It details a material change involving a subscription agreement for convertible debentures and warrants, which is a financing activity. The document is not a full financial report but a regulatory filing reporting a material change event. It does not contain comprehensive financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not an announcement of voting results, board changes, or legal proceedings. The content focuses on a capital raising transaction, which fits the Capital/Financing Update category. The document length is about 5257 characters, sufficient to provide substantive details about the financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-08-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a financing agreement where Tetra Bio-Pharma Inc. secured $6,000,000 through convertible debentures and warrants with Alpha Blue Ocean. It details the terms of the subscription agreement, use of proceeds, and includes forward-looking statements. There are no financial statements or comprehensive financial data presented, nor is this a report or transcript. The content focuses on capital raising and financing activities. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2022-08-12 English
News release - English.pdf
Regulatory Filings
2022-08-10 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Tetra Bio-Pharma Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended May 31, 2022. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3862 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-07-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.